Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.64 |
| ▸ | CCR3 | P51677 | 2/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12404102 | 1.00 | GBA1 (0.64) | GBA1CCR3MGLLSLC18A3PRMT3 | |
| SCHEMBL5527739 | 1.00 | GBA1 (0.64) | GBA1CCR3MGLLSLC18A3PRMT3 | |
| SCHEMBL674276 | 0.89 | GBA1 (0.71) | GBA1CCR3MGLLPRMT3CARM1 | |
| SCHEMBL2027845 | 0.89 | GBA1 (0.71) | GBA1CCR3MGLLPRMT3CARM1 | |
| Ammonia Solution, Strong SCHEMBL1432566 | 0.86 | GBA1 (0.68) | GBA1CCR3MGLLPRMT3CARM1 | |
| Hydrochloric Acid SCHEMBL4797146 | 0.84 | GBA1 (0.65) | GBA1CCR3MGLLPRMT3CARM1 | |
| SCHEMBL6977373 | 0.83 | GBA1 (0.59) | GBA1CCR3MGLLSLC18A3PRMT3 | |
| SCHEMBL8414688 | 0.83 | GBA1 (0.59) | GBA1CCR3MGLLSLC18A3PRMT3 | |
| SCHEMBL8416050 | 0.83 | GBA1 (0.59) | GBA1CCR3MGLLSLC18A3PRMT3 | |
| SCHEMBL14260213 | 0.80 | GBA1 (0.52) | GBA1CCR3MGLLSLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | GBA1 639/4885CCR3 3256/4885MGLL 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.